ReviewResearch and reports in urology2015
Managing the adverse events of intravesical bacillus Calmette-Guérin therapy.
Review in Research and reports in urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Pooled it
- Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.European urology oncology · 2024Trial
- The Effect of Intravesical Bacillus Calmette-Guerin Treatment on Sexual Functions and Mental Health in Male and Female Patients Diagnosed with Non-Muscle Invasive Bladder Cancer.Urology research & practice · 2026Article
- Structural Characterization and Immunostimulatory Activity of a New Slightly Branched β-glucan in Sporisorium reilianum-Infected Sorghum Head Smut.Chemistry & biodiversity · 2026Article
- Clinical Presentation, Management, and Outcomes ofOpen forum infectious diseases · 2026Article
- Intravesical therapy for bladder cancer causing disseminated tuberculosis and perforated viscus: a case report.Journal of surgical case reports · 2026Article
- Whole Genome Sequencing of ClinicalInternational journal of molecular sciences · 2025Article
- Time to abandon routine urine analysis prior to Bacillus Calmette-Guérin administration in asymptomatic patients.BJUI compass · 2025Article
- Assessment of T1 and T2 Relaxation-Time Changes in NMIBC Tissue After 5-ALA Photodynamic Therapy Using Quantitative Magnetic Resonance Imaging.Biomedicines · 2025Article
- Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study.Journal of clinical medicine · 2025Article
- Progress on liposome delivery systems in the treatment of bladder cancer.RSC advances · 2025Review
- Afebrile tuberculous prostatic abscess with rectal fistula after intravesical Bacillus Calmette-Guérin immunotherapy.IJU case reports · 2025Article
- Tolerability and efficacy of induction Bacillus Calmette-Guérin for non-muscle invasive bladder cancer.Bladder (San Francisco, Calif.) · 2025Article
- Article
- Bacillus Calmette-Guérin (BCG) prostato-epididymitis in a patient treated for a non-invasive urothelial cancer: A case report.IDCases · 2024Article
- Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy.Bladder cancer (Amsterdam, Netherlands) · 2023Article
- Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.Frontiers in oncology · 2023Review
- How to reduce bacillus Calmette-Guérin discontinuation in patients with severe functional impairment.Current urology · 2022Article
- Review
- Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.Journal for immunotherapy of cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper provides recommendations on the management of complications arising from intravesical treatment with bacillus Calmette-Guérin (BCG) for nonmuscle-invasive bladder tumors. There is minimal recommendations currently available as randomized trials on the side effects of intravesical BCG are lacking and severe complications are usually described in case reports only. All physicians giving intravesical BCG should be aware of the possible complications that could arise and how to treat these. The incidence of bladder irritation, general malaise, and fever is very high, while severe complications remain rare. Approximately 8% of patients have to stop treatment because of these complications. BCG infections and reactions can occur anywhere in the body, and may happen straight away or even several months or years after BCG treatment, making early diagnosis difficult. Additionally, correct diagnosis is hampered by the uncertain appearance of BCG in tissue and body fluid. An essential step in the management complications arising from BCG is written information for both the family doctor and the patient on the possible adverse events and their management. Recent data demonstrated that none of the earlier advocated methods to prevent BCG toxicity are valid: lowering the dose, tuberculostatic drugs, or oxybutynin. Severe complications are treated with three or four tuberculostatics over 3-12 months, depending on the severity of the situation. Corticosteroids are an essential therapy in BCG septicemia. Nonsteroidal anti-inflammatory drugs and corticosteroids can manage efficiently the immunological complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.